Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1107 | 9272 | 33.0 | 77% |
Classes in level above (level 3) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
48 | 92304 | HAEMOPHILIA//HEMATOLOGY//THROMBOSIS AND HAEMOSTASIS |
Classes in level below (level 1) |
ID, lev. below | Publications | Label for level below |
---|---|---|
1739 | 2431 | MASSIVE TRANSFUSION//THROMBOELASTOMETRY//THROMBOELASTOGRAPHY |
2863 | 2053 | CYP2C9//VKORC1//WARFARIN |
3798 | 1830 | RIVAROXABAN//DABIGATRAN//APIXABAN |
6306 | 1436 | INTERNATIONAL SENSITIVITY INDEX//PROTHROMBIN TIME//INTERNATIONAL NORMALIZED RATIO |
8590 | 1170 | BRIDGING ANTICOAGULATION//BRIDGING THERAPY//BLOOD THINNERS |
21677 | 352 | PROTHROMBIN COMPLEX CONCENTRATE//PROTHROMBIN COMPLEX CONCENTRATES//ANTICOAGULATION REVERSAL |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | WARFARIN | Author keyword | 472 | 33% | 13% | 1177 |
2 | CYP2C9 | Author keyword | 412 | 63% | 5% | 420 |
3 | VKORC1 | Author keyword | 382 | 81% | 3% | 233 |
4 | RIVAROXABAN | Author keyword | 281 | 54% | 4% | 360 |
5 | MASSIVE TRANSFUSION | Author keyword | 209 | 76% | 2% | 145 |
6 | DABIGATRAN | Author keyword | 186 | 45% | 3% | 311 |
7 | INTERNATIONAL NORMALIZED RATIO | Author keyword | 180 | 56% | 2% | 222 |
8 | APIXABAN | Author keyword | 169 | 55% | 2% | 213 |
9 | INR | Author keyword | 134 | 55% | 2% | 166 |
10 | PROTHROMBIN TIME | Author keyword | 124 | 43% | 2% | 219 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | WARFARIN | 472 | 33% | 13% | 1177 | Search WARFARIN | Search WARFARIN |
2 | CYP2C9 | 412 | 63% | 5% | 420 | Search CYP2C9 | Search CYP2C9 |
3 | VKORC1 | 382 | 81% | 3% | 233 | Search VKORC1 | Search VKORC1 |
4 | RIVAROXABAN | 281 | 54% | 4% | 360 | Search RIVAROXABAN | Search RIVAROXABAN |
5 | MASSIVE TRANSFUSION | 209 | 76% | 2% | 145 | Search MASSIVE+TRANSFUSION | Search MASSIVE+TRANSFUSION |
6 | DABIGATRAN | 186 | 45% | 3% | 311 | Search DABIGATRAN | Search DABIGATRAN |
7 | INTERNATIONAL NORMALIZED RATIO | 180 | 56% | 2% | 222 | Search INTERNATIONAL+NORMALIZED+RATIO | Search INTERNATIONAL+NORMALIZED+RATIO |
8 | APIXABAN | 169 | 55% | 2% | 213 | Search APIXABAN | Search APIXABAN |
9 | INR | 134 | 55% | 2% | 166 | Search INR | Search INR |
10 | PROTHROMBIN TIME | 124 | 43% | 2% | 219 | Search PROTHROMBIN+TIME | Search PROTHROMBIN+TIME |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | FACTOR XA INHIBITOR | 473 | 59% | 6% | 530 |
2 | DIRECT THROMBIN INHIBITOR | 364 | 62% | 4% | 381 |
3 | DABIGATRAN ETEXILATE | 319 | 59% | 4% | 357 |
4 | CYP2C9 | 316 | 59% | 4% | 356 |
5 | DAMAGE CONTROL RESUSCITATION | 297 | 77% | 2% | 203 |
6 | FRESH FROZEN PLASMA | 280 | 40% | 6% | 552 |
7 | CYTOCHROME P4502C9 | 276 | 70% | 2% | 229 |
8 | MASSIVE TRANSFUSION | 250 | 59% | 3% | 284 |
9 | WARFARIN | 230 | 19% | 12% | 1091 |
10 | INTERNATIONAL NORMALIZED RATIO | 224 | 48% | 4% | 347 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 18 | 10% | 2% | 168 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Usefulness of standard plasma coagulation tests in the management of perioperative coagulopathic bleeding: is there any evidence? | 2015 | 7 | 62 | 87% |
Pharmacology and management of the vitamin K antagonists | 2008 | 794 | 318 | 55% |
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban | 2014 | 22 | 60 | 93% |
Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? | 2014 | 22 | 47 | 85% |
Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy | 2014 | 23 | 109 | 78% |
How I treat target-specific oral anticoagulant-associated bleeding | 2014 | 19 | 67 | 82% |
A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy | 2015 | 3 | 34 | 82% |
The pathogenesis of traumatic coagulopathy | 2015 | 3 | 77 | 82% |
Haemostatic management of cardiac surgical haemorrhage | 2015 | 4 | 64 | 61% |
Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists Systematic Review and Meta-Analysis of Bleeding and Thromboembolic Rates | 2012 | 73 | 42 | 83% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TRANSLAT INJURY | 49 | 49% | 0.8% | 72 |
2 | C ITAL REG BLOOD BANK | 45 | 60% | 0.5% | 49 |
3 | ECAA CENT IL | 33 | 100% | 0.1% | 13 |
4 | ECAA | 26 | 100% | 0.1% | 11 |
5 | TRANSFUS MED SECT | 25 | 42% | 0.5% | 46 |
6 | EAA CENT IL | 23 | 100% | 0.1% | 10 |
7 | HAEMOSTASIS THROMBOSIS | 23 | 24% | 0.9% | 82 |
8 | TRAUMA CRIT CARE ACUTE CARE SURG | 18 | 40% | 0.4% | 36 |
9 | TRANSLAT INJURY ACUTE CARE SURG | 15 | 82% | 0.1% | 9 |
10 | SHAANXI PROV CLIN | 13 | 80% | 0.1% | 8 |
Related classes at same level (level 2) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000018973 | ATRIAL FIBRILLATION//PULMONARY VEIN ISOLATION//CATHETER ABLATION |
2 | 0.0000016012 | CARDIOPULMONARY BYPASS//APROTININ//PERFUSION-UK |
3 | 0.0000015466 | PULMONARY EMBOLISM//VENOUS THROMBOEMBOLISM//DEEP VEIN THROMBOSIS |
4 | 0.0000015375 | VITAMIN K//PHYLLOQUINONE//VITAMIN K2 |
5 | 0.0000015112 | HEPARIN INDUCED THROMBOCYTOPENIA//ARGATROBAN//LEPIRUDIN |
6 | 0.0000010492 | PROTEIN C//ACTIVATED PROTEIN C//TISSUE FACTOR |
7 | 0.0000010159 | HAEMOPHILIA//HAEMOPHILIA A//VON WILLEBRAND DISEASE |
8 | 0.0000009671 | TRANSFUSION//VOX SANGUINIS//BLOOD TRANSFUSION |
9 | 0.0000007453 | DYSFIBRINOGENEMIA//AFIBRINOGENEMIA//DYSFIBRINOGEN |
10 | 0.0000007350 | JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE//TRAUMA SYSTEMS//TRAUMA SYSTEM |